Our Shielded Living Therapeutics^TM platform combines advanced cell differentiation and engineering techniques with innovations in biocompatible materials, potentially enabling our products to produce a wide range of functions or therapeutics molecules that may be missing or deficient in the body, including proteins, enzymes or other therapeutic molecules.

Our pipeline primarily spans a range of endocrine and lysosomal diseases, with the current focus on diabetes. Our product candidates are designed to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes or chronic suppression of the patient’s immune system.